...
首页> 外文期刊>Journal of Clinical Oncology >Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
【24h】

Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.

机译:治疗诱发的病理性坏死:预测接受新辅助治疗高度肢端软组织肉瘤的患者局部复发和生存的指标。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine whether treatment-induced pathologic necrosis correlates with local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. PATIENTS AND METHODS: Four hundred ninety-six patients with intermediate- to high-grade extremity soft tissue sarcomas received protocol neoadjuvant therapy. All patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tumor necrosis in the resected specimens. RESULTS: The 5- and 10-year local recurrence rates for patients with > or = 95% pathologic necrosis were significantly lower (6% and 11%, respectively) than the local recurrence rates for patients with less than 95% pathologic necrosis (17% and 23%, respectively). The 5- and 10-year survival rates for the patients with > or = 95% pathologic necrosis were significantly higher (80% and 71%, respectively) than the survival rates for the patients with less than 95% pathologic necrosis (62% and 55%, respectively). Patients with less than 95% pathologic necrosis were 2.51 times more likely to develop a local recurrence and 1.86 times more likely to die of their disease as compared with patients with > or = 95% pathologic necrosis. The percentage of patients who achieved > or /= 95% pathologic necrosis increased to 48% with the addition of ifosfamide as compared with 13% of the patients in all the other protocols combined. CONCLUSION: Treatment-induced pathologic necrosis is an independent predictor of both local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. A complete pathologic response (> or = 95% pathologic necrosis) correlated with a significantly lower rate of local recurrence and improved overall survival.
机译:目的:确定在高度肢端软组织肉瘤接受新辅助治疗的患者中,治疗诱发的病理坏死是否与局部复发和总体生存相关。患者与方法:496例中至上肢四肢软组织肉瘤患者接受了新辅助治疗方案。所有患者在新辅助治疗后均接受手术切除,并对切除标本中的肿瘤坏死进行了病理学评估。结果:病理性坏死≥95%的患者的5年和10年局部复发率显着低于病理性坏死少于95%的患者的5年局部复发率(分别为6%和11%)(17 %和23%)。 ≥95%病理性坏死的患者的5年和10年生存率(分别为80%和71%)显着高于小于95%病理性坏死的患者(62%和55%)。病理性坏死少于95%的患者与病理性坏死≥95%的患者相比,发生局部复发的可能性高2.51倍,死于疾病的可能性高1.86倍。添加异环磷酰胺后,达到或超过95%病理坏死的患者比例增加到48%,而所有其他方案的总和为13%。结论:治疗诱发的病理坏死是接受高级别肢端软组织肉瘤新辅助治疗的患者局部复发和总体生存的独立预测指标。完整的病理反应(>或= 95%病理坏死)与明显降低的局部复发率和改善的总生存率相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号